BerGenBio has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for bemcentinib in combination with an anti-PD-(L)1 agent for the treatment of patients with

Heartseed Inc. and Novo Nordisk A/S have entered into an exclusive worldwide collaboration and license agreement for development, manufacturing and commercialization of Heartseed’s HS-001. HS-001 is an investigational cell therapy

Sigrid Therapeutics has signed a collaboration agreement with the Japanese company AGC Si-Tech. “Discussions with AGC have been underway for years, and we’re very satisfied that we’ve now landed an

AstraZeneca’s Tagrisso (osimertinib) has been approved in the European Union (EU) for the adjuvant treatment of adult patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small

OnDosis and German B2B pharmaceutical company Tiefenbacher Group initiate four new development projects targeting ADHD, rare diseases and transplantation medicine. Last year, the two companies began cooperating on an ADHD

The company has announced two exclusive license agreements with The University of Texas MD Anderson Cancer Center related to MAGE-A4 and VGLL1 targeting allogeneic “off-the-shelf” TCR-NK cell therapies for the